Cullinan Therapeutics Inc.

This is an early-stage study to test the safety and tolerability of a new drug called CLN-978 for people with moderate to severe lupus. It will involve about 24 participants who have not responded well to at least two standard lupus treatments. The main goal is to see how safe th…

This is a first-in-human study testing a new drug called CLN-049 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the drug moves through th…

This early-stage study is testing the safety and side effects of an experimental drug called CLN-978 in people with active, moderate to severe Sjogren's disease. The drug is given as an injection under the skin. Researchers will enroll 36 participants to monitor for any adverse r…